Back to Search
Start Over
Interim analysis of key clinical outcomes from a phase 1/2 study of weekly intravenous DNL310 (brain-penetrant enzyme replacement therapy) in MPS II
- Source :
- Molecular Genetics and Metabolism. 138:107231
- Publication Year :
- 2023
- Publisher :
- Elsevier BV, 2023.
Details
- ISSN :
- 10967192
- Volume :
- 138
- Database :
- OpenAIRE
- Journal :
- Molecular Genetics and Metabolism
- Accession number :
- edsair.doi...........97c81e9979efef396314d9673a17e816
- Full Text :
- https://doi.org/10.1016/j.ymgme.2022.107231